Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC in Mild to Moderate Alzheimer's Disease
NCT06185543Phase 2Terminated
- Sponsor
- NeuroSense Therapeutics
- Start
- Nov 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PrimeC in Alzheimer's disease (AD), sponsored by NeuroSense Therapeutics. Started Nov 2023; status: terminated.
02
Drugs
PrimeC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06185543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06185543.